Phase 1 Trial Testing IMV’s Tailored Immunotherapy Doses First Ovarian Cancer Patient
IMV’s Phase 1 clinical trial evaluating a personalized immunotherapy that targets mutated proteins called neoepitopes in ovarian cancer patients has started dosing participants, the company announced.
“The first immunization of the first ovarian cancer patient with our personalized, patient-specific neoepitopes developed at the University of Connecticut using our proprietary technology ... is a major milestone for us,” Pramod K. Srivastava, PhD, MD, director of the Neag Comprehensive Cancer Center at the University of Connecticut School of Medicine and the trial’s lead investigator, said in a press release.
Cancers typically develop when cells undergo changes in their genetic makeup. While these mutations usually give them an advantage over other cells, allowing them to proliferate and survive unchecked, they also compromise the cells' disguise from the immune system.
The logic is simple. A genetic mutation will produce a new, abnormal protein — called a neoantigen — that is seen by the immune system as foreign, cuing immune cells to attack the cancer cells. In particular, immune cells target a small portion of neoantigens, called the neopitope.
Based on this process, researchers have been developing strategies that prime immune cells toward these abnormal proteins. IMV's approach is to develop a personalized cancer vaccine that contains multiple neoepitopes from a cancer patient. When delivered into the blood, immune cells attac
IMVpatient-specific neoepitopespersonalized immunotherapyPhase 1 trialUniversity of Connecticutvaccine
" Patricia Inacio, PhD : Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.."